Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Pioneering
personalized medicine
in epigenetics

Oryzon now

22 February 2021

ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020

Read more
15 February 2021

Article by our CEO, Carlos Buesa, discussing epigenetics & CNS personalised medicine published in the February issue of MedNous

Read article
11 February 2021

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

Read more

ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders

About us
Epigenetics

Epigenetics is a regulatory system that controls gene expression without affecting the makeup of the genes themselves. Regulation of gene transcription and translation are key biological determinants for cellular differentiation and function, and transcriptional imbalances play a significant pathogenic role in a number of human diseases.

More info
Therapeutic programs

ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with cancers and CNS disorders. We are able to identify and validate biomarkers and therapeutic targets through our epigenetic platform and translate them into advanced and personalized therapies.

More info
Latest News
  • 22 February 2021

    ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020

    • Read more about ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020
  • 11 February 2021

    ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

    • Read more about ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia
  • 10 February 2021

    ORYZON to present new clinical data and corporate updates at conferences in February and March

    • Read more about ORYZON to present new clinical data and corporate updates at conferences in February and March
All News
Upcoming events
  • 9-10 March 2021

    H.C. Wainwright Global Life Sciences Conference

    • More details about H.C. Wainwright Global Life Sciences Conference
  • 9-14 March 2021

    15th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD 2021

    • More details about 15th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD 2021
  • 10-11 March 2021

    14th Annual European Life Sciences CEO Forum 2021

    • More details about 14th Annual European Life Sciences CEO Forum 2021
All Events
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy